| |
Wednesday, May 14, 2025 | 11am ET / 8am PT Biotech success isn’t just about great science—it’s about building a compelling commercial narrative from day one. Join us to explore how early commercialization planning, powered by real-world insights, can maximize an asset’s potential. Our discussion will uncover strategies to integrate commercial thinking into R&D. Register now. 
|
|
Today’s Big NewsApr 24, 2025 |
| By Angus Liu Halozyme is not holding back against Merck & Co. in their injectable Keytruda patent dispute, having now followed through on a verbal warning with a lawsuit. |
|
|
|
By Gabrielle Masson Armed with $240,000, the “Vaccine Integrity Project” is launching to provide a safeguard for vaccine use amid widespread misinformation campaigns and federal cuts to public health programs. |
By Nick Paul Taylor Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback. The candidate fell short in a phase 2 psoriasis trial, prompting the French drugmaker to pull back from plans to develop the molecule as a monotherapy. |
By Zoey Becker The Pharmaceutical Care Management Association urges drugmakers to lower the list prices of their medicines in a new series of digital ads that launched across Washington, D.C. |
|
Tuesday, May 6, 2025 | 9am ET / 6am PT This webinar will explore how to use AI-driven tools for timely data-driven decisions that are critical to securing approvals, expediting market entry and sustaining competitive strength. Register now. 
|
|
By Conor Hale Boston Scientific believes it can absorb the hit based on the continuing growth of its franchises in cardiology and urology. |
By Kevin Dunleavy Thermo Fisher has joined the life science investment splurge in the U.S. with a new $2 billion plan over the next four years “strengthening American innovation, manufacturing and economic competitiveness,” the company said. |
By Darren Incorvaia A study of almost 34,000 people in rural China has revealed that lowering blood pressure can reduce the risk of dementia in patients with hypertension. |
By Fraiser Kansteiner Bristol Myers Squibb remains confident that Cobenfy can come out ahead of its recent clinical defeat, and it's planning to start a group of “difficult studies” this year in three indications. |
By James Waldron Big Pharma M&A will likely take a hit if the U.S. government lives up to its threats of imposing tariffs on the industry, Roche’s CEO has warned. |
By Zoey Becker The company's CEO, Rob Davis, is joining his industry peers in pushing for greater rewards for innovation in countries outside of the U.S., where drug prices are often substantially lower. |
By James Waldron Mosaic Therapeutics has secured the latest pieces in its combination medicine strategy by licensing two clinical stage tumor drugs from fellow British biotech Astex Pharmaceuticals. |
By Andrea Park Like several other biopharmas before it, UCB has turned to perhaps the most recognizable dermatologist in the U.S. to add star power to a skin condition-focused campaign. |
Fierce podcasts Don’t miss an episode |
| This week on "Podnosis," Yumlish CEO Shireen Abdullah joins us to discuss how culturally tailored nutrition education is helping tackle diabetes—and why looming federal budget cuts could derail that progress. |
|
|---|
|
|
|
Wednesday, May 28, 2025 | 11am ET / 8am PT Join us to learn more about Integrated Drug Discovery (IDD), and explore the complexity of integrating multidisciplinary functions, including chemistry, biology, pharmacology, project and data management, advanced technologies, and regulatory compliance. Learn how to navigate the drug discovery journey and overcome common challenges. Register now. 
|
|
eBook Typical vaccine development timelines have averaged 10 years, but the time from the SARS-CoV-2 genetic sequence’s release to the submission of the first vaccine clinical trial data for regulatory review was a mere 314 days. In IQVIA Laboratories’ Vaccine eBook we focus on how contract research organizations (CROs) can best leverage strategic partnerships with sponsors to prepare for the next pandemic. Sponsored by: IQVIA |
Whitepaper Is your clinical trial data truly reliable? Learn how a combined approach using Imaging Core Labs and Endpoint Adjudication Committees (EAC) can minimize risk, control costs, and strengthen your study from the ground up. Don’t leave success to chance—arm yourself with the insights to stay ahead. Sponsored by: WCG |
Research We interviewed 15 biopharma leaders on the critical success factors for building a Best Practice customer-facing organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
